Andere Sprachen Spruce Biosciences, Inc.

Aktien

A2QD65

US85209E1091

SPRB

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 02.05.2024			% 5 Tage	% 1. Jan.
0,7416 ^USD	+3,37 %		+5,79 %	-74,69 %

14.03.	Top Absteiger am Mittag	MT
14.03.	Sektor-Update: Aktien des Gesundheitswesens am Donnerstagnachmittag niedriger	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Spruce Biosciences : Failure to Satisfy Listing Rule - Form 8-K	11:10
Spruce Biosciences to Participate in May Investor Conferences	01.05.
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting	30.04.
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting	22.04.
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB	05.04.
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB	27.03.
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	21.03.
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB	19.03.
North American Morning Briefing : Inflation -2-	15.03.
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	14.03.
Top Midday Decliners	14.03.
Sector Update: Health Care Stocks Lower Thursday Afternoon	14.03.
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	14.03.
Spruce Biosciences 2023 Loss Narrows; to Cut 21% Workforce After Trial Misses Target; Shares Sink	13.03.
Spruce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13.03.
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates	13.03.
Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH	13.03.
Spruce Biosciences, Inc. Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH	13.03.
Top Premarket Decliners	13.02.
Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	30.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Spruce Biosciences, Inc.

Aktien

A2QD65

US85209E1091

SPRB

Andere Sprachen

Filter